Provided by Tiger Fintech (Singapore) Pte. Ltd.

CANSINOBIO

33.950
+3.55011.68%
Volume:3.32M
Turnover:110.30M
Market Cap:8.40B
PE:-20.80
High:34.750
Open:30.700
Low:30.700
Close:30.400
Loading ...

CanSino Biologics Narrows Loss in Q1

MT Newswires Live
·
Yesterday

CanSino Biologics' 2024 Loss Narrows as Revenue Surges 137%

MT Newswires Live
·
27 Feb

CanSino Biologics Gets Clinical Trial Appproval from NMPA for Influenzae Type B Vaccine

MT Newswires Live
·
24 Feb

BRIEF-CanSino Biologics Says DTcP-Hib-MCV4 Combined Vaccine Obtains Clinical Trial Approval By NMPA China

Reuters
·
24 Feb

BUZZ-CanSino jumps as NMPA grants priority review status to infant vaccine application

Reuters
·
10 Feb

CanSino Biologics Combined Vaccine for Infants Gets Priority Review Status from Chinese Regulator

MT Newswires Live
·
07 Feb

Chinese Regulator Accepts CanSino Biologics' New Drug Application for Tetanus Vaccine

MT Newswires Live
·
06 Feb

BUZZ-China's CanSino climbs on forecasting narrowing loss, higher FY revenue

Reuters
·
20 Jan

CanSino Biologics Expects Narrower Attributable Loss in 2024

MT Newswires Live
·
17 Jan

CanSino Biologics Gets Registration Certificate for Meningitis Vaccine in Indonesia

MT Newswires Live
·
30 Dec 2024

CanSino Biologics Begins Trial for Tetanus, Diptheria, Acellular Pertussis Shots

MT Newswires Live
·
23 Dec 2024

CanSino Biologics Polio Vaccine Trials Gets First Patient Enrollment

MT Newswires Live
·
23 Dec 2024

CanSino Biologics' NDA for Combined Vaccine Accepted in China

MT Newswires Live
·
16 Dec 2024

Stock Track | CanSinoBIO Soars 5.18% on Positive Regulatory Update for Meningococcal Vaccine

Stock Track
·
27 Nov 2024

CanSino's Supplemental Application for Meningococcal Vaccine Accepted in China

MT Newswires Live
·
27 Nov 2024

CanSino Biologics Enrolls First Patient in Phase 1 Trial for Haemophilus Influenzae Vaccine

MT Newswires Live
·
19 Nov 2024

CanSino Biologics Inc.'s (HKG:6185) Price Is Right But Growth Is Lacking After Shares Rocket 37%

Simply Wall St.
·
12 Nov 2024